$Rezolve AI (RZLV.US)$
This acquisition represents a compelling strategic move with notable financial implications. The $55M enterprise value compared to $30M expected 2025 revenue implies a forward EV/Revenue multiple of 1.83x, which appears reasonable for a high-margin AI technology business in the current market environment.
The all-equity transaction structure is particularly significant for three reasons:
It preserves Rezolve's cash position for operational growth and fut...

$Moderna (MRNA.US)$ is scheduled to report fourth-quarter and full-year 2024 earnings on 14 Feb before the opening bell.
While a major portion of Moderna revenues is expected to be generated from the sales of its COVID-19 vaccine, but we need to understand that we are already into matured phase of the post-pandemic, and the vaccine sales would likely declined from one year ago level due to the lower dema...